These findings offer compelling preclinical support for further clinical investigation of PD-1/PD-L1-directed immunotherapies along with CCR2 antagonism against several tumor types, particularly in light of the accessibility of CCR2 small molecule inhibitors [202]. This evidence concerns the gene CCR2 and neoplasm.